±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 349  |  »Ø¸´: 1

cainiaodui

гæ (СÓÐÃûÆø)

[ÇóÖú] ·­ÒëÇóÖú

Medical Science Liaisons (MSLs) are field-based Medical Affairs Associates of Novartis, who develop peer-to-peer relationships with Key Opinion Leaders/Medical Experts/Key Stakeholders and members of the scientific community, utilizing scientific and medical evidence-based non-promotional materials. They strategically prepare and support the development, launch and commercialization of Novartis products through scientific exchange, seeking external insight to shape Novartis understanding of the therapeutic environment. Their activities begin up to two years prior to launch of a new molecule. They respond to unsolicited requests for scientific information and provide clinical trial support. Additionally, Senior MSLs participate and often lead special projects and specific initiatives, leveraging their extensive experience and strategic insight.
Compliance with applicable policies, procedures and other regulations.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

cher0424

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-08-23 13:56:28
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-09-04 08:29:58
ҽѧ¿ÆÑ§ÁªÂçÔ±ÊÇŵ»ªµÄҽѧÊÂÎñÏà¹ØµÄÈËÔ±£¬ÔËÓûùÓÚÖ¤¾ÝµÄ·ÇÐû´«ÐԵĿÆÑ§ºÍҽѧ²ÄÁÏ£¬¸ºÔð·¢Õ¹ÓëÖ÷Òª¹Ø¼üÒâ¼ûÁìµ¼Õß/ҽѧר¼Ò/¹Ø¼üµÄÀûÒæÏà¹ØÕߺͿÆÑ§Ð­»á³ÉÔ±µÄ¶ÔµÈ¹ØÏµ¡£ËûÃÇÔÚÕ½ÂÔÉÏ×¼±¸¡¢Ö§³Öŵ»ª²úÆ·µÄµÄ·¢Õ¹¡¢ÉÏÊкÍÉÌÒµ»¯£¬Í¨¹ý¿ÆÑ§µÄ½»Á÷ºÍѰÇóÍⲿµÄ¶´²ìÁ¦À´ËÜÔìŵ»ª¶ÔÓÚÖÎÁÆ»·¾³µÄÀí½â¡£ËûÃÇÔÚзÖ×ÓÉÏÊÐǰµÄ2Ä꿪ʼ¹¤×÷¡£ËûÃǸºÔð½â´ðδÓÐÈ·¶¨´ð°¸µÄ¿ÆÑ§ÐÅÏ¢ºÍÌṩÁÙ´²ÊÔÑéÖ§³Ö¡£ÁíÍ⣬¸ß¼¶Ò½Ñ§¿ÆÑ§ÁªÂçÔ±½èÁ¦ÓÚËûÃǹ㷺µÄ¾­ÑéºÍÕ½ÂÔÑ۹⣬²ÎÓëºÍͨ³£Áìµ¼ÏîÄ¿ºÍ¾ßÌå¾Ù´ë¡£
×ñÑ­ÊÊÒ˵ÄÕþ²ß£¬³ÌÐòºÍºÍÆäËû¹æ¶¨¡£
2Â¥2014-08-23 13:54:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ cainiaodui µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 086000ÉúÎïÓëÒ½Ò©Çóµ÷¼Á +3 ÀÏÌì¾ì¹ËÖ®ÈË 2026-03-31 3/150 2026-04-05 22:24 by syh9288
[¿¼ÑÐ] 280Çóµ÷¼Á +4 Àîrien 2026-04-04 4/200 2026-04-05 18:44 by imissbao
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +10 @taotao 2026-03-30 10/500 2026-04-05 17:57 by jj987
[¿¼ÑÐ] ²ÄÁÏ»¯¹¤306·ÖÕÒºÏÊʵ÷¼Á +14 ²×º£ÇáÖÛe 2026-04-04 14/700 2026-04-05 09:53 by ÖìÔÆ»¢202
[¿¼ÑÐ] ²ÄÁÏר˶322·Ö +11 ¹þ¹þ¹þºðºðºð¹þ 2026-04-02 11/550 2026-04-04 23:37 by ÓÀ×ÖºÅ
[¿¼ÑÐ] Äܶ¯µ÷¼Á326ר˶ +4 wan112233 2026-04-04 4/200 2026-04-04 22:47 by yu221
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤306·ÖÕÒµ÷¼Á +23 ²×º£ÇáÖÛe 2026-04-02 27/1350 2026-04-04 21:52 by laoshidan
[¿¼ÑÐ] 0703Çóµ÷¼Á +6 zizimo 2026-03-31 6/300 2026-04-04 14:16 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 278Çóµ÷¼Á +6 Yy7400 2026-04-03 6/300 2026-04-04 09:53 by zhangdingwa
[¿¼ÑÐ] »¯¹¤µ÷¼Á303·Ö£¬¹ýËļ¶ +28 ÆÜÎà´ý·ç 2026-04-02 28/1400 2026-04-03 21:40 by qlm5820
[¿¼ÑÐ] 301Çóµ÷¼Á +14 A_JiXing 2026-04-01 14/700 2026-04-03 18:31 by lsÁõ˧
[¿¼ÑÐ] ר˶ 351 086100 Ò²ÊÇ¿¼µÄ²Ä¿Æ»ù ±¾¿ÆÒ²ÊDzÄÁÏ +8 202451007219 2026-04-02 8/400 2026-04-03 09:50 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ²ÄÁÏ¿¼Ñе÷¼Á +10 Gs´óÍõ 2026-04-02 10/500 2026-04-03 09:47 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] һ־Ըɽ¶«´óѧ»¯Ñ§Ó뻯¹¤Ñ§Ôº²ÄÁÏÓ뻯¹¤×¨Ë¶£¬360·ÖÇóµ÷¼Á +4 ²»Ô¸Í¸Â¶ÐÕÃûµÄË 2026-04-02 4/200 2026-04-03 09:29 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] Ò»Ö¾Ô¸aÇø211£¬085601-307·ÖÇóµ÷¼Á +13 µ³¼ÎºÀ 2026-03-31 26/1300 2026-04-03 08:33 by 495374996
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ +6 whatÕÅ 2026-04-01 7/350 2026-04-02 16:48 by zzsw+
[¿¼ÑÐ] 311Çóµ÷¼Á +14 À¶ÔÂÁÁÁÁ 2026-03-30 14/700 2026-04-02 12:18 by 1753564080
[¿¼ÑÐ] 0805Çóµ÷¼Á +8 ÊÇË®·Ö 2026-03-31 8/400 2026-04-02 10:46 by guanxin1001
[¿¼ÑÐ] 339Çóµ÷¼Á +5 zjjkt 2026-03-31 5/250 2026-04-01 09:18 by JourneyLucky
[¿¼ÑÐ] ±§Ç¸ +3 ÌïºéÓÐ 2026-03-30 3/150 2026-03-30 19:11 by ÃÔºýCCPs
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û